Improving Diagnosis of Bladder Cancer

该项目的长期目标是提高对一种常见人类癌症的检测 通过非侵入性排尿测试在膀胱中产生。膀胱癌是最常见的 4"^ 男性和 5 英寸最常见，约有 70,500 例新病例，14,600 人死于该病 2009年在美国。据估计，该中心有近 30 万名患者接受定期监测 美国通过无创（尿液）和微创（膀胱Barbotage， 膀胱镜检查和活检）技术。因此，开发能够检测的新型生物标志物 采用非侵入性方法治疗膀胱肿瘤具有重要的临床意义。在这笔赠款中，我们建议 通过新颖的方法补充现有的多机构 Aurora 激酶 A FISH 测试生物标志物验证试验 FISH 标记并探讨极光激酶 A 在膀胱癌进展中的作用。我们将比较 aurora 的特异性和敏感性 FISH 测试辅以一组新颖的 FISH 标记和其他标记 已知的针对排空尿液沉积物的非侵入性膀胱癌检测测试，例如尿液细胞学检查和 市售多染色体 FISH 试剂盒（称为 UroVysion）和 NMP22 即时检测。一个 将通过全器官组织学和遗传图谱 (WOHGM) 开发一系列新型 FISH 标记 该策略与基于高分辨率 (IM) lllumina SNP 的基因分型相结合，提供了独特的 有关与膀胱癌发展平行的基因组改变的时间顺序的信息 对侵袭性疾病的早期场效应。我们强有力的初步数据表明，这种方法提供了独特的 有机会设计可解决膀胱癌发展特定阶段的新型生物标志物 沿着这些浅表乳头状和高级非乳头状侵入路径。此外，我们建议 研究极光激酶A及其常规通路在膀胱癌进展为侵袭性中的作用 疾病和远处转移。本项目的具体目标如下： 具体目标 1：开发 膀胱癌的新型 FISH 标记物组。具体目标 2：验证一组新颖的 FISH 生物标志物 用于膀胱癌。具体目标 3：研究极光激酶 A 在膀胱癌生长中的作用， 血管生成、侵袭和转移。

The long-term objective of this project is to improve the detection of one of the common human cancers arising in the bladder by non-invasive voided urine-based tests. Bladder cancer is the 4"^ most frequent in men and 5"" most common overall with approximately 70,500 new cases and 14,600 deaths from the disease in 2009 in the United States. It is estimated that nearly 300,000 patients are regularly monitored in the United States through a vanety of non-invasive (urine) and minimally invasive (bladder barbotage, cystoscopy, and biopsy) techniques. Therefore, the development of novel biomarkers that can detect bladder tumors by a non-invasive approach is of major clinical significance. In this grant, we propose to complement the existing Multi-Institutional Aurora kinase A FISH Test Biomarker Validation Trial by novel FISH markers and explore the role of Aurora kinase A in bladder cancer progression. We will compare the specificity and sensitivity of aurora A FISH test complemented by a panel of novel FISH markers with other known noninvasive bladder cancer detection tests for voided urine sediments such as urine cytology and commercially available multi-chromosomal FISH kit known as UroVysion, and NMP22 point-of-care test. A panel of novel FISH markers will be developed by whole-organ histologic and genetic mapping (WOHGM) strategy combined with high resolution (IM) lllumina SNP-based genotyping, which provides unique information on the chronology of genomic alterations that parallel the development of bladder cancer from early field effects to invasive disease. Our strong preliminary data indicate that this approach offers a unique opportunity to design novel biomarkers that may address the specific phases of bladder cancer development along these superficial papillary and high grade nonpapillary Invasive pathways. Moreover, we propose to investigate the role of aurora kinase A and its regular pathway in bladder cancer progression to invasive disease and distant metastasis. The specific aims of this project are as follows: Specific Aim 1: Develop a panel of novel FISH markers for bladder cancer. Specific Aim 2: Validate a novel set of FISH biomarkers for bladder cancer. Specific Aim 3: Investigate the role of Aurora kinase A in bladder cancer growth, angiogenesis, invasion and metastasis.